Why Matinas BioPharma Stock crashed today
Actions of Matinas BioPharma Holdings (NYSEMKT: MTNB) were down 32.7% as of 3:01 p.m. EST Monday. The sharp drop came after the company announced disappointing results from a Phase 2 clinical study of Lypdiso in lowering triglycerides.
Matinas had good news and bad news. The good news was that Lypdiso beat Amarin‘s (NASDAQ: AMRN) Vascepa in increasing the levels of eicosapentaenoic acid (EPA) in the blood of study participants. It wasn’t even close, with Lypdiso demonstrating a 46% increase in EPA from baseline compared to Vascepa.
But the bad news was for investors. The primary endpoint of the late stage study was percent change from baseline in triglyceride levels. Matinas hoped to show that Lypdiso was the winner hands down against Vascepa. However, Lypdiso failed to meet this primary endpoint.
Despite this failure, patients taking Lypdiso had lower triglyceride levels than patients taking Vascepa. The relative improvement, however, was not statistically significant.
Is the biotechnology stocks to recover after today’s massive sale? Perhaps. Matinas hopes to find a partner to work with on a pivotal late stage Lypdiso study. CEO Jerome Jabbour said company management believes Phase 2 data “indicates the potential for a strong reduction in cardiovascular risk” with Lypdiso.
This article represents the opinion of the author, who may disagree with the “official” recommendation position of a premium Motley Fool consulting service. We are motley! Challenging an investment thesis – even one of our own – helps us all to think critically about investing and make decisions that help us become smarter, happier, and richer.